Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort

SUPPLEMENTAL DATA

Marc Blondon¹, Alexandre Bodmer², Laure Thouvenin², Thomas Lecompte¹, Marc Righini¹, Pierre Fontana¹, Alessandro Casini¹

Affiliations: ¹ Division of Angiology and Hemostasis; ² Department of Oncology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Supplementary Table 1. Change in other measurements of thrombin generation, with and without activated protein C or thrombomodulin, stratified by use of tamoxifen and aromatase inhibitors, and adjusted differences in change of these measures between the groups

	Tamoxifen (n=42)				Aromatase inhibitors (n=65)				Difference between tamoxifen	
									and aromatase inhibitor	
	T1	T2	Absolute	Р	T1	T2	Absolute	P value	Adjusted absolute	P-value
	mean	mean	difference	value	mean	mean	difference		difference *	
	(SD)	(SD)	(95%CI)		(SD)	(SD)	(95%CI)		(95%CI)	
Lag time	3.4 (0.7)	3.0 (0.5)	-0.4	<0.00	3.8 (0.8)	3.9 (0.7)	0.0	0.76	-0.5 (-0.7 to -0.3)	<0.001
[min]			(-0.5 to -0.3)	1			(-0.1 to 0.1)			
Time to	7.3 (1.3)	6.5 (1.0)	-0.8	<0.00	8.2 (1.3)	8.1 (1.3)	-0.1	0.45	-1.0 (-1.3 to -0.7)	<0.001
peak [min]			(-1.0 to -0.6)	1			(-0.2 to 0.1)			
ETP with	933.1	1087.3	+154.2 (+103.2	<0.00	820.8	852.1	+31.4 (-19.0 to	0.22	+180.2 (+94.9 to	<0.001
APC	(306.9)	(270.4)	to +205.2)	1	(203.1)	(282.2)	81.7)		+265.5)	
[nMxmin]										

ETP with	589.9	813.6	+223.7 (+165.2	<0.00	406.1	431.8	+25.7 (-14.2 to	0.2	+229.9 (+149.1 to	<0.001
тм	(283.5)	(304.6)	to +282.3)	1	(215.6)	(211.1)	+65.6)		+310.7)	
[nMxmin]										

*Adjusted for age, BMI, current smoking and baseline value at T1

APC = activated protein C ; ETP = endogenous thrombin potential ; TM = thrombomodulin ; SD = standard deviation